Momentum Trades

MomentumOptionsTrading.com Weekly Wrap for 8/21/11

10:40pm (EST)

1.  Market Summary

2.  Is Dendreon (DNDN) a Steal in the Low Teens?

3.  Selling Puts on Stocks You Like Can Be Beneficial

4.  Earnings

5.  Weekly Wrap Portfolio Update

6.  Week Ahead

(To view the charts, please log into the Members Area and go to the Weekly Wrap Premium section)

= = = = = = = = = = = = = = =

1.  Market Summary –

Chalk another week up to the bears, as weak economic news and less-than-stellar earnings continued to weigh on the market.  The biggest headline came on Thursday when France and Germany so no way to a “euro bond”, and an uptick in weekly jobless claims added up to another rough week for the bulls.

The bulls were able to continue their winning ways on Monday from the prior week by adding another 2% to their 3-session rally as they pushed through the first level of resistance.  The Dow was pushing 11,500; the S&P 500 was above 1,200; and the Nasdaq was trading at 2,555.

On Tuesday, the bears took back half of Monday’s gains as nervousness over talks between German Chancellor Merkel and French President Sarkozy, who got together to discuss the euro’s problems, left Wall Street on edge.  While most traders penciled-in good news, it wasn’t, and nothing really got resolved.

Wednesday was a flat day for the indexes although the Nasdaq finished in the red by 0.5%.  There was a little caution ahead of Thursday’s jobs numbers, and we were figuring on a flat report, but there were others nuggets of info due after the opening bell that worried us.

The market was already in turmoil before Thursday’s open as fresh worries over the euro caused another round of selling pressure but the real shocker was the Philly Fed number which came in at negative 30.  Jobless Claims were up to 408,000 and back over 400K.

We knew going into Friday, the momentum was to the downside but the bulls put up a fight until lunchtime before packing it in for the weekend.  As a result, the major averages fell almost exactly on our downside targets as traders’ seemed hesitant in staying long.

The Dow dropped 173 points, or 1.6%, on Friday to end at 10,817.  The index traded to a low of 10,801 and we mentioned last week that we could have a sell-off on headline news down to 10,800.  The next target if this level fails would be 10,600 (green line, purple circles) but we have been mentioning a possible drop to 10,200-10,000 (red line, black circles).  As far as resistance, the 11,000 level (black line, orange circles), followed by 11,500 (blue line, red circles) could cap any rally.  As a reminder, the official target for a bear market is 10,250 for the Blue-Chips.   For the week, the Dow declined 451 points, or 4%, and is down 6.6% for the year, or 760 points.

The S&P 500 sank 17 points, or 1.5%, and settled at 1,123.  The index kissed 1,122 and we said the 1,125 level (black line, orange circles) would come into play once 1,175 and 1,150 were taken out.  There is further risk down to 1,050 (green line, red circles) and bear market territory begins on a drop below 1,100.  As far as resistance, if 1,150 is cleared, the bulls will attempt a run back to 1,175 ((red line, blue circles), then 1,200.  For the week, the S&P dropped double-nickels (55 points), or 4.7%, and is down 10.7% YTD, or 134 points.

The Nasdaq fell 39 points, or 1.6%, and finished at 2,341. Tech reached an intraday bottom of 2,338 which was just above the low of 2,331 on August 9.  We mentioned the possibly of 2,350 (black line, orange circles) triggering again last Sunday night if the 2,400 level was violated which will now serve as short-term resistance, followed by 2,500 (blue line, green circles).  We also warned of a trip to 2,200 (green line, red circles) if support doesn’t hold and an official bear market for Tech would occur on a drop below 2,300.  For the week, Tech gave back 166 points, or 6.6%, and is down 311 points, or 11.7% for 2011.


The S&P Volatility Index (^VIX, 43.05, up 0.38) surged to a high of 45 on Thursday and Friday (green line) which represented resistance from January 2009 (black line, orange circles).  As you can see, the VIX traded above 80 on the 2008 continued selloff and the bulls will need to get back below 30 (orange line, blue circles) to restore confidence in the market.

We mentioned last week that Ben Bernanke was headed out to Jackson Hole but it is this week and he will give a speech on Friday.  We said “last time out the boys took a fishing trip, the markets rallied for a few months afterwards” and Wall Street is hoping for similar reprise of last year’s QE2 announcement.

We aren’t sure what good another stimulus package would bring and the market could rally on any announcement but much of the money so far has been a waste, let’s face it.  Although stocks look cheap, and we are nibbling, we are also fully prepared for a lower market.  There are some solid companies trading at low double-digit PE’s and below the S&P’s historical average, but, a full-blown bear market could drag some stocks to single-digit PE’s as you will see below.

It doesn’t really matter to us which way the market rolls because we would use the Daily to play the downside although the stocks in our Weekly portfolio would suffer.  However, we could then double up in a month or two on some of the positions to average our cost down.

Futures are showing a slight pop ahead of Monday’s opening bell but it’s way too early to tell where they will be Monday morning:  Dow futures (+38); S&P (+4); Nasdaq (+10).

= = = = = = = = = = = = = = =

Key of Technicals Used In Following Article


2.  Is Dendreon (DNDN) a Steal in the Low Teens?

Dendreon (DNDN, $12.06, up $0.75) fell off a cliff, plunging nearly 70% from $36 to just under $12 on August 4.  However, we believe the stock is on sale, and investors would be wise to snap up Dendreon at current levels.

In April of last year, Dendreon received FDA approval to market its advanced prostate cancer treatment, Provenge, causing the stock to settle at the $35-$40 range.  Earlier this month, the company released financial and operational results well below analysts’ expectations and significantly lowered 2011 guidance in the process.  The selloff was due to the fact that the launch of Provenge was having trouble getting recommendations from doctors due to reimbursement problems.

Expected annual revenue was decreased from between $1.5 billion and $2 billion to between $500 million and $1.2 billion.  The $93,000 treatment costs $31,000 per infusion and extends the life of patients by an average of 4 months.  This price is much higher than the $40,000-$75,000 range analyst expected and the average cost of $60,000 for prostate treatment.

After debating on reimbursement for Provenge, Medicare agreed to pay for it in March.  The problem is that many doctors still don’t know about this.  As more and more doctors learn about this, sales should rise.  And since Medicare is legally prohibited from considering price when deciding whether to pay for a new treatment, the high cost shouldn’t hinder sales.

The infused drug is a first-of-a-kind treatment in which each dose is customized to work with a patient’s immune system.  A patient’s own immune cells are removed and taken to a lab where they are altered to attack the prostate cancer cells before being injected back into the patient.  Since the treatment uses the patient’s immune system, there are few to no side effects.  This is a significant improvement from chemotherapy, which has significant side effects.  And although extending life by an average of 4 months seems low, it is double that of chemotherapy.

Additionally, Provenge is only currently approved to treat patients in their last stage of prostate cancer, but a study in phase III trials is testing the treatment for earlier stages of prostate cancer, with promising results.  If the trial succeeds and the drug’s use can be expanded, the U.S. market for Provenge can easily triple to between $1.5 billion and $4.5 billion.  The current market cap of Dendreon is $1.8 billion, meaning Provenge revenue could easily meet or exceed the value of the company alone.

Further, Dendreon has $4.19 a share in cash.  Thus, the company only needs to make $7.87 per share, or about $1.17 billion, to trade at book value.  The upper range of current estimated Provenge sales, as noted earlier, is $1.2 billion.  Also, using that range and a multiple of 3-times sales gives Dendreon between $1.5 billion and $3.6 billion in revenue.  On top of that, the market also needs to consider the rest of the company’s rich pipeline.

Dendreon has five patents on its cancer and antigen technology and three processing plants.  It also has half a dozen other drug trials in works for various forms of cancer.  Surely, these trials, patents, and plants are worth something.

Lastly, there is a possibility that a bigger pharmaceutical company will buy Dendreon.  Back in 2006, the company partnered with Genetech, now part of Swiss giant Roche, on cancer treatments, in which Genetech agreed to purchase $2 million of Dendreon’s stock.  Thus, Roche could be a potential suitor.  However, several big pharmaceutical giants, including Pfizer (PFE, $17.67, down $0.04), are losing patents on their blockbuster drugs and could use another drug to replace the lost income so Dendreon would make sense at a cheap price.

The sales graphs below show the company’s past sales (6/10, 9/10, 12/10, 3/11, 6/11) nearly matches estimated sales (9/11, 12/11).  Adding sales for 3/11, 6/11, 9/11, and 12/11 gives $215 million in sales.  Before the fall, analysts were predicting $400 million in sales.  Thus, sales estimates were cut about 50%, but the shares decreased by about 67%.  This would conclude that the stock should be at least $17.50 a share.

One brokerage firm wasn’t scared to stick its toes in shark waters and issued a 12-month price target of $18 for Dendreon.  At $12, the stock is much closer to its low target of $6.00 than its high target of $36.00 made by the 20 analysts recorded by Thomson/First Call.  Mean target is $18.10, and median target is $17.50.  Using a scale of 1.0 as a strong buy and 5.0 as a sell, the average rating of the stock was 2.6, unchanged from a week ago.


Current Month

Last Month

Two Months Ago

Three Months Ago

Strong Buy

9

9

9

8

Buy

9

9

7

7

Hold

5

5

5

5

Underperform

1

1

1

0

Sell

1

1

1

0

However, given the current market conditions, this would be an aggressive target but possible on renewed takeover chatter.

= = = = = = = = = = = = = = =

3.  Selling Puts on Stocks You Like Can Be Beneficial

The current volatility has caused option premiums to soar, especially put options, which can be a bullish strategy when selling them.  This strategy is also risky because you don’t own the stock and shares could move lower, causing you to buy the options back or the stock can be “put” to you for the strike price you sold the options at even though its lower in the market.  In other words, if you sold a put option with a strike price of $10 and shares are at $5 at the time of expiration, you will have to buy the stock at $10.

If you sell a put you are hoping the stock will go up in value but if it doesn’t, you won’t mind owning it.

Here is a closer look.

If a stock is at $20 and the $17.50 put option for the month is trading at $1, you would place an order to “sell to open” the option you have targeted and would collect the $100 premium.  Each option contract represents 100 shares so $1 x 100 gives you the $100 that goes into your account instantly for each option contract you sell.  You are doing this because you think the stock will stay above $17.50.

If the stock stays above this level by the time the option expires, the contract will not be exercised, and you keep the premium.

If the stock is at $16, it is below the $17.50 strike price.  Whoever owns the right to that option you sold is going to sell the stock to you at $17.50 instead of going to the market and selling it for $16.  So, for every option contract you sell short, it would cost you $1,750 because you would have to buy 100 shares at $17.50 apiece.

However, since you collected $100 premium from selling the option, your breakeven point is $16.50 for the stock.  You could then wait for a rebound back above this level or higher to make a profit or get out at even if shares were “put” to you.

We know many of you may not have gotten that the first time so let’s do a real life example with Dendreon which is near $12.

The Dendreon September 12 puts (DNDN110917P00012000, $1.30, down $0.10) are at $1.30 a contract which means the premium is $130 to buy or sell the option.  If you think shares will hold $12 or better by mid-September then you would sell the option.  If you thought the stock was going to go to $8, you would buy the option.

The 52-week low is $9.22 so we know shares could retest this level, and possibly $5, so we are prepared for a test to lower levels if this is the case.  At $9, we might buy more shares of Dendreon and then another third at $5 if there is a continued selloff.  If we bought shares at $12, or they were “put’ to us, and then $9, and $5 – our average cost would be $8.67 a share ($26 – $12+$9+$5 – divided by 3).

This is the risk with selling put options, but it’s hard to call it “risk” if you end up owning a great stock at discounted prices.  Also, if you don’t feel shares will recover, you could close the position, take a small loss, and move on instead of averaging down.

Remember, the reason we are selling put options is for the premium, and if we sold a call option on Dendreon, the losses could be unlimited since shares could trade to whatever price the market is demanding.

If you sold a September 12 call (DNDN110917C00012000, $1.40, down $0.05) and Dendreon is at $25, you would have to sell someone the stock at $12 even though shares are at $25.  Not good.

As you can see, there is less downside risk, to a degree, because shares can only trade to $0 and Dendreon is at $12.  We aren’t sure if and when Dendreon will ever trade back to $50 which is its all-time peak but we feel it’s time to go bottom fishing.

We aren’t sure at what point we will sell the September 12 puts because we want to see how shares act to start the week, but that is the game plan and we will send out a Trade Alert if we do.

= = = = = = = = = = = = = = =

4.  Earnings

The companies in BOLD, we are looking at as possible trades and we may list call or put options on them in our Daily Newsletter.  If they become official recommendations, we sent out Trade Alerts or include them in our 9am and 1pm updates that come out during the week (Quotes are as of Friday’s close, 8/19/11).

MONDAY

American Defense Systems (EAG, $0.11, up $0.02), Bridgford Foods (BRID, $10.18, up $0.71), Brown Shoe (BWS, $7.16, up $0.05), China Mass Media (CMM, $1.19, down $0.04), Eastern Light Capital (ELC, $2.72, Flat), Focus Media Holding (FMCN, $27.51, down $0.93), Geopetro Resources (GPR, $0.34, up $0.01), Golden Minerals (AUMN, $11.58, up $0.19), Heico  (HEI, $44.17, down $0.98), Immunomedics (IMMU, $3.10, up $0.09), Overland Storage (OVRL, $2.50, up $0.23), Qiao Xing Universal Resources (XING, $1.04, down $0.01), Raven Industries (RAVN, $45.28, up $0.72), Shanda Interactive Entertainment (SNDA, $30.86, down $0.18), Shangpharma (SHP, $8.88, down $0.04), Sharps Compliance (SMED, $3.27, up $0.06), Tandy Brands Accessories (TBAC, $1.90, up $0.03), Urologix (ULGX, $0.88, Flat)

TUESDAY

American Woodmark (AMWD, $13.68, up $0.23), Avago Technologies (AVGO, $28.29, down $0.32), Corinthian Colleges (COCO, $2.26, down $0.26), Daktronics (DAKT, $8.41, up $0.13), Gerber Scientific (GRB, $11.00, up $0.03), H J Heinz (HNZ, $51.85, down $0.22), La Z Boy (LZB, $7.19, down $0.02), Medtronic (MDT, $31.29, up $0.04), MelCo Crown Entertainment (MPEL, $12.06, down $0.52),Pacific Sunwear of California (PSUN, $20.6, down $0.02), Shanda Games (GAME, $4.85, up $0.22), Stealthgas (GASS, $4.08, down $0.10), Tangoe (TNGO, $10.44, up $0.35), Tofutti Brands (TOF, $1.94, Flat), Williams Sonoma (WSM, $28.88, up $0.07), Zanett (ZANE, $0.55, Flat)

WEDNESDAY

American Eagle Outfitters (AEO, $10.97, down $0.36), Applied Materials (AMAT, $10.82, down $0.17), BioDelivery Sciences International (BDSI, $3.10, down $0.03), CDC Software (CDCS, $3.93, up $0.07), Collective Brands (PSS, $9.51, up $0.16), Express (EXPR, $16.75, up $0.27), Guess (GES, $30.32, down 0.81), John B Sanfilippo & Son (JBSS, $7.03, down $0.30), Perceptron (PRCP, $6.14, up $0.04), rue21 (RUE, $25.30, down $0.63), Sigma Designs (SIGM, $7.86, down $0.11), Synovis Life Technologies (SYNO, $14.36, up $0.35), TiVo (TIVO, $7.88, down $0.14), Toll Brothers (TOL, $14.98, down $0.54), Versant (VSNT, $10.37, down $0.27)

THURSDAY

Aruba Networks (ARUN, $16.34, down $0.76), Bebe Stores (BEBE, $6.05, Flat), Big Lots (BIG, $30.09, down $0.09), Cyberonics (CYBX, $23.70, down $0.29), Dollar Financial (DLLR, $18.01, down $0.34), Energy Conversion Devices  (ENER, $0.71, down $0.01), Fred’s (FRED, $10.56, up $0.03), Hormel Foods (HRL, $27.70, down $0.34), Krispy Kreme Doughnuts (KKD, $7.16, down $0.05), LJ International (JADE, $2.31, down $0.09), Magma Design Automation (LAVA, $5.12, down $0.01), Micros Systems (MCRS, $39.51, down $0.19), Omnivision Technologies (OVTI, $23.83, down $0.26), Pandora Media (P, $13.02, up $0.11), Patterson Companies (PDCO, $27.81, down $0.09), Regis (RGS, $13.57, down $0.13), Sanderson Farms (SAFM, $40.44, down $1.60), Shoe Carnival (SCVL, $26.00, down $0.66), Vimpelcom (VIP, $10.48, down $0.21)

FRIDAY

Isoray (ISR, $1.14, up $0.03), Madison Square Garden (MSG, $22.78, up $0.19), Tiffany (TIF, $57.36, down $1.85)

= = = = = = = = = = = = = = =

5. Weekly Wrap Covered Call Portfolio Update (Closing prices as of 8/19/11)

WEEKLY WRAP CLOSED TRADES for 2011: DNDN +9%, PCX +13%, SGEN +26%, TIVO +34%, REDF +11%, PCX +7

Clean Energy Fuels (CLNE, $11.91, up $0.20)

September 13 calls (CLNE110917C00013000, $0.55, up $0.05)

Original Entry Price:  $12.53 (8/12/11)

Lowered Price from Selling Options: $11.53

Exit Target: $13+

Return: 3%

Stop Target: None

Actions:  The 52-week low for shares is $11.16, which was hit earlier this month and represents strong support (black line, red circles).  We like the company for the long haul and shares traded to a high of $12.76 on Wednesday.  A break back above $12.75 (green line, purple circles) would be bullish.

We recommended buying the stock at $12.53 on 8/12/11 and for every 100 shares to sell the September 13 calls for $1.  This lowered the cost basis to $11.53.

If shares are called away at $13 in mid-September the trade will make 13%.


MGM Resorts (MGM, $9.50, down $0.50)

September 12 calls (MGM110917C00012000, $0.15, down $0.05)

Original Entry Price:  $11.73 (8/12/11)

Lowered Price from Selling Options: $10.83

Exit Target: $12+

Return: -12%

Stop Target: None

Action:  MGM is being tossed out with the bath water, but we still like this baby.  Shares broke serious support just above $10 (black line, red circles) last week which now represents short-term resistance.  There is further risk down to $9 (green line, orange circles) and a break below this level would present an incredible buying opportunity.  The company still owns 80% of the premier properties in Vegas and has its footprints in China.  The stock is trading at a forward PE of 2.

We recommended buying the stock at $11.73 on 8/12/11 and for every 100 shares to sell the September 12 calls for 90 cents.  This lowered the cost basis to $10.83.

If shares are called away at $12 in mid-September the trade will make 11%.


General Electric (GE, $15.09, down $0.25)

September 16 calls (GE110917C00016000, $0.35, down $0.10)

Original Entry Price:  $15.98 (8/12/11)

Lowered Price from Selling Options: $15.23

Exit Target: $12+

Return: -1%

Stop Target: None

Action:  GE pays a dividend of 4% and is a steal in the mid-teens.  If you own the stock when the dividend is payable then you will receive it although you sold a call option against the shares and as long as the contract isn’t exercised.  We didn’t buy the stock for the dividend because we believe shares are headed back to $20 over the next 6-12 months.  GE held support at $15 (green line, red circles) all week but there is risk down to $14 (black line, orange circles).

We recommended buying the stock at $15.98 on 8/12/11 and for every 100 shares to sell the September 16 calls for 75 cents.  This lowered the cost basis to $15.23.

If shares are called away at $16 in mid-September the trade will make 5%.


Newpark Resources (NR, $7.92, up $0.29)

Original Entry Price:  $9.45 (7/27/11)

Lowered Price from Selling Options: $8.95

Exit Target: $10+

Return: -20%

Stop Target: None

Action:  The August 10 calls expired Friday and we will wait until shares get back over $9 before we write another option.  Newpark traded to a low of $6.57 (black line, red circles) earlier this month which represented the March low after a breakout and strong support.  There is a chance the stock dips to $6 (green line, purple circles) which is the next layer of support if $6.50 falls.

We recommended buying the stock at $9.45 on 7/27/11 and for every 100 shares to sell the August 10 calls for 50 cents.  This lowered the cost basis to $8.95.

Rambus (RMBS, $10.58, down $0.27)

September 17 calls (RMBS110917C00017000, $0.15, down $0.05)

Original Entry Price:  $15.60 (7/22/11)

Lowered Price from Selling Options: $14.95

Exit Target: $20+

Return: -29%

Stop Target: None

Action:  Shares are right at support (black line, red circles) and a break below $10 could lead to $8-$7 (red line, blue circles) if current levels don’t hold.  Resistance at $12 (green line, orange circles) will need to be cleared to swing the momentum back into the bulls favor.

We recommended buying the stock at $15.60 on 7/22/11 and for every 100 shares to sell the September 17 calls for 65 cents.  This lowered the cost basis to $14.95.

If shares are called away at $17 in mid-September the trade will make 14%.

Symantec (SYMC, $15.42, down $0.39)

Original Entry Price:  $18.77 (6/8/11)

Lowered Price from Selling Options: $18.17

Exit Target: $20+

Return: -13%

Stop Target: None

Action:  The August 20 options expired Friday and we will wait for the stock to trade back near $18 before writing another call.  We were hoping $16 (red line, green circles) would hold after shares hit a low of $15.58 the prior week and bounced.  There is a chance $15 (blue line, orange circles) is tested and a break of this level would bring $14 (black line) into play.  We love this company for the security options it offers and, over the next 12-24 months, we think somebody will step up to the plate and buy Symantec or shares will be well over $20 either way.

We recommended buying the stock at $18.77 on 6/8/11 and for every 100 shares to sell the July 19 calls for 60 cents.  This lowered the cost basis to $18.17.

On 7/18/11 we recommended selling the August 20 calls for 35 cents which lowered the cost basis to $17.82.


Rare Element Resources (REE, $8.16, down $0.21)

Original Entry Price: $12.38 (5/31/11)

Lowered Price from Selling Options: $11.23

Exit Target: $10+

Return: -27%

Stop Target: None

Action:  Shares could be headed to the $7.50 level (red line, blue circles) over the near-term if $8 falls and there is further risk down to $6 (green line, black circle).  Once shares break above $10 again, we will look to write another call option.

We recommended buying the stock at $12.38 on 5/31/11 and for every 100 shares to sell the July 12 calls for $1.15.  This lowered the cost basis to $11.23.


Vivus (VVUS, $7.15, up $0.10)

Original Entry Price:  $7.93 (5/11/11)

Lowered Price from Selling Options: $7.13

Exit Target: $10+

Return: 0%

Stop Target: None

Action:  The August 9 calls expired Friday.  Vivus hit a low of $6.13 earlier this month which is strong support (red line) and made a nice rebound.  Resistance is still strong at $8 (green line) but look at the bullish rectangle (purple box) for this chart which has been in place since last September.  We are looking at the September or October calls to sell this week so stay tuned for a possible Trade Alert at some point.


We recommended buying the stock at $7.93 on 5/11/11 and for every 100 shares to sell the June 8 calls for 50 cents.  This lowered the cost basis to $7.43.

On 7/1/11 we recommended selling the August 9 call option for $0.30 which lowered the cost basis to $7.13.


AKS Steel Holding (AKS, $7.79, down $0.04)

Original Entry Price:  $15.93 (5/2/11)

Lowered Price from Selling Options: $14.58

Exit Target: $20+

Return: -47%

Stop Target: None

Action:  The August calls expired Friday and shares fell below another key layer of support just under $10 (red line, green circles) last week.  There is further risk down to $6 (black line, orange circles) which is where we would double-up and notice the strong rebounds each time shares traded to this level (blue box).


We recommended buying the stock at $15.93 on 5/2/11 and for every 100 shares to sell the May 16 calls for 50 cents.  This lowered the cost basis to $15.43.

On 7/1/11 we recommended selling the August 16 call option for $0.85 which lowered the cost basis to $14.58.


American Capital (ACAS, $7.75, down $0.21)

Original Entry Price:  $9.73 (4/19/11)

Lowered Price from Selling Options: $8.68

Exit Target: $15+

Return: -11%

Stop Target: None

Action:  The August 10 calls expired Friday and shares are once again at long-term support just under $8 (red line, black circles).  There is further risk down to $7 (green line, orange circles), then $6, but we expect $7 to hold.  We will look to sell a September or October call if shares rebound back to $10.

We recommended buying the stock at $9.73 on 4/19/11 and for every 100 shares to sell the June 10 call for 50 cents.  This lowered the cost basis to $9.23.

On 7/1/11 we recommended selling the August 10 call option for $0.55 which lowered the cost basis to $8.68.


Cisco Systems (CSCO, $15.08, up $0.07)

Original Entry Price:  $17.14 (3/17/11)

Lowered Price from Selling Options: $16.28

Exit Target: $20+

Return: -7%

Stop Target: None

Action:  The August 17 calls expired Friday and Cisco is back at $15 (green line, red circles) which is crucial support.  There is a chance for a dip to $14 and we will wait for the stock to get back near $16 before writing another call option.

We recommended buying the stock at $17.14 on 3/17/11 and for every 100 shares to sell the May 18 call for 56 cents.  This lowered the cost basis to $16.58.

On 7/22/11 we recommended selling the August 17 calls for 30 cents which lowered the cost basis to $16.28.


Spreadtrum Communications (SPRD, $15.88, down $0.29)

Entry Price:  $23.45 (2/7/11)

Lowered Price from Selling Options: $21.48

Exit Target: $30

Return: -26%

Stop Target: None

Action:  Spreadtrum continues to look strong in a weak market and has made a nice recovery after testing support just below $14 (orange line, black circles).  Resistance is strong at $18 which is where we will look for a breakout and the opportunity to write another covered call.


Shares opened at $23.43 on 2/7/11 and the March calls could have been sold for 95 cents.  This lowered the cost basis to $22.48.

On 4/11/11 we recommended selling the May 22.50 call option for $1.00 which lowered the cost basis to $21.48.


DryShips (DRYS, $2.74, down $0.21)

January 2012 7.50 call (DRYS120121C00007500, $0.07, flat)

Entry Price:  $5.25 (1/03/11)

Lowered Price from Selling Options: $4.60

Exit Target: $8

Return: -40%

Stop Target: None

Action:  Continue to hold and wait for a break back above $3 (red line, green circles).

DryShips opened at $5.37 on 1/3/11 and shares were at $5.25 shortly after the bell.  The January call options could have been sold for 65 cents which lowered the cost basis to $4.60.

If shares are over $7.50 by January 2012, the stock will be “called away” and the trade will make over 60%.

= = = = = = = = = = = = = = =

6.  Week Ahead

There are no economic reports scheduled for Monday.

On Tuesday, the market will get a fresh look at New Home Sales for July.  We doubt this will have an impact on the market because Wall Street isn’t expecting much after last month’s print of just 312,000 units.

For Wednesday, Durable Goods will be released before the open while the FHFA Housing Price Index report is due out 30 minutes after the open.  We will also get the weekly update on Crude Inventories.

Thursday will be all about the jobs numbers as Initial Claims and Continuing Claims hit the Street before the bell.

Friday will feature a number of key reports, starting with the latest Gross Domestic Product (GDP) figures before the market opens.  These numbers will likely have a big impact on the market, as well as the final Michigan Sentiment Survey, which is due shortly after trading begins.

]]>

Scroll to Top